News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Nivolumab with and without ipilimumab in solid tumors of high mutational burden – Journal for ImmunoTherapy of Cancer
Photo from pediatriconcall.com
Aug 9, 2024, 05:53

Nivolumab with and without ipilimumab in solid tumors of high mutational burden – Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer shared a post on X, about recent paper published in Journal for ImmunoTherapy of Cancer:

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Authors: Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo A. Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S. P. Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola.

Journal for ImmunoTherapy of Cancer

”New JITC article: Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.”

Journal for ImmunoTherapy of Cancer

Source: Journal for ImmunoTherapy of Cancer/X

Alexandra Leary Anthony Gonçalves cancer David S. P. Tan Georgia Kollia Iwona Lugowska Jacqueline Vuky Jean-Pierre Delord Jennifer Friedmann JITC Jonathan Baden Journal for ImmunoTherapy of Cancer Julieta Grasselli Lorena Lupinacci Marina Tschaika Martin Richardet Massimo Di Nicola Mauricio Burotto Michael Schenker Michele Maio Misena Pacius Neeltje Steeghs Ning Huang nivolumab OncoDaily Oncology Paolo A. Ascierto Parul Doshi Patrick Schöffski pilimumab Quyen Duong Ruta Slepetis Sai Vikram Vemula solid tumors Somasekhar Konduru Tudor-Eliade Ciuleanu
Special Coverage
Blog
Mar 20, 2025, 15:17
Dean Crowe: $75 MILLION for kids, teens, and young adults fighting cancer
Blog
Mar 20, 2025, 14:47
Eric Zwanenburg: The Princess Máxima Center and Google Cloud are developing an AI tool called Capricorn
Blog
Mar 20, 2025, 11:46
What happens when women not only have a seat at the table but also shape the agenda? - Kearney
Blog
Mar 20, 2025, 11:39
Susanna Fletcher Greer: Understanding cellular communication in colorectal adenocarcinoma
Blog
Mar 20, 2025, 11:30
Abstract Submission open for MAP 2025 - ESMO
Science
Mar 20, 2025, 11:22
Ashish M. Kamat: Impact of fellowship training on outcomes and complication rates of radical prostatectomy
Radiotherapy
Mar 20, 2025, 11:18
What Is Superficial Radiotherapy and How It Works? Pros and Cons
Blog
Mar 20, 2025, 11:13
Francisco Conesa Buendía: AstraZeneca’s $1B Bet on In Vivo CAR-T - A Potential Game-Changer for Cancer Therapy
Blog
Mar 20, 2025, 11:01
Polikalipo Kagina: World Radiotherapy Day 2025 Officially Set for September 7
Science
Mar 20, 2025, 10:52
Nihar Desai: Central Nervous System Manifestations of Graft-Versus-Host Disease
Science
Mar 20, 2025, 10:42
Catherine Alix-Panabières: New Insights into Circulating Tumor Cells in Metastatic Breast Cancer
Blog
Mar 20, 2025, 10:35
Jasmine Kamboj: Empowering Oncologists with Jonathan Ticku